Talis Biomedical Co. (NASDAQ:TLIS – Get Rating) was down 1% on Friday . The company traded as low as $0.59 and last traded at $0.60. Approximately 109,802 shares were traded during mid-day trading, a decline of 12% from the average daily volume of 124,413 shares. The stock had previously closed at $0.61.
Talis Biomedical Stock Performance
The company has a 50-day moving average of $0.54 and a 200-day moving average of $0.67.
Get Talis Biomedical alerts:Talis Biomedical (NASDAQ:TLIS – Get Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.24). Talis Biomedical had a negative return on equity of 59.90% and a negative net margin of 2,119.66%. The business had revenue of $0.80 million during the quarter, compared to the consensus estimate of $0.20 million. Research analysts predict that Talis Biomedical Co. will post -4.03 earnings per share for the current year.
Hedge Funds Weigh In On Talis Biomedical
A number of large investors have recently bought and sold shares of the business. Prelude Capital Management LLC raised its position in shares of Talis Biomedical by 36.2% during the 1st quarter. Prelude Capital Management LLC now owns 256,395 shares of the company's stock worth $362,000 after purchasing an additional 68,126 shares during the period. Millennium Management LLC bought a new position in Talis Biomedical during the 2nd quarter worth $164,000. Finally, Renaissance Technologies LLC increased its position in Talis Biomedical by 549.3% in the second quarter. Renaissance Technologies LLC now owns 107,765 shares of the company's stock worth $88,000 after buying an additional 91,167 shares during the period. Institutional investors own 47.08% of the company's stock.Talis Biomedical Company Profile
(Get Rating)
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19.
Featured Stories
- Get a free copy of the StockNews.com research report on Talis Biomedical (TLIS)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
Receive News & Ratings for Talis Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talis Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.